PCR products obtained using the Ipsogen kit were subject to agarose gel electrophoresis. Both samples had single prominent bands which were the same size as control samples (data not shown). These results are consistent the mutant probe not binding to the mutant allele in both patients and are consistent with codon 617 and 618 mutations being on the same allele.
In conclusion, the Ipsogen kit failed to identify 2 samples with JAK2 617VϾF mutations which had additional mutations. The Ipsogen kit would likely miss other 617VϾF samples which have a second mutation and other exon 14 mutations. [5] [6] [7] [8] Since the JAK2 617VϾF mutation (or other functionally similar mutations) are part of the revised WHO criteria for myeloproliferative disorders, 1 failure to detect this mutation may result in misdiagnosis.
These findings highlight the broader issue patents impose upon clinical laboratories and the potential for inferior diagnostic testing and missed mutations. This issue came to a forefront on May 12, 2009, when the American Civil Liberties Union filed a lawsuit against Myriad Genetics, which has exclusive rights to perform BRCA1 and BRCA2 mutation testing. 9 The lawsuit claims patents on these genes are unconstitutional and invalid. Moreover, BRCA1/2 mutations have been missed. 10 We evaluated the Ipsogen kit because it was cost-prohibitive to pay the substantial upfront fee and additional royalty on test sales using a "home-brew" assay. It is unfortunate that such restrictions can compromise patient care, and it will be interesting to see the outcome of the Myriad Genetics lawsuit and whether this paves the way to prevention of monopolies created by gene patenting. 
To the editor:
The role of CBF␤ in AML1-ETO's activity Identification of interacting proteins essential for oncogenic functions of leukemia-associated transcription factors is important for understanding the underlying transformation mechanisms and designing effective cancer therapeutics. 1 We have recently found that homo-oligomerization property, but not its interaction with core-binding factor beta subunit (CBF␤), is critical for AML1-ETO-mediated transformation of primary hematopoietic cells. 2 Strikingly, the conclusion on CBF␤ requirement contradicts another study by Roudaia et al, which reported an essential function of CBF␤ interaction for AML1-ETO activity based on an AML1-ETO double-point mutant (Y113A/T161A). 3 One possible explanation for these discrepancies is the use of different point mutants in these studies. 4 To this end, we have generated an identical AML1-ETO Y113A/T161A mutation used in the study of Roudaia et al and compared it with our M106V point mutant in the transformation assay. In contrast to cells transduced with empty vector or the AML1-ETO DNA binding mutant that rapidly lost their proliferative capacity, cells transduced with the CBF␤ defective mutants including Y113A/ T161A could still form significant numbers of third and subsequent rounds of colonies in the serial replating assay ( Figure 1A ). Despite reduced number (an average of 12 different experiments), the resultant colonies exhibited very similar morphology and immunophenotypes as wild-type AML1-ETO transformed cells ( Figure 1B-C and supplemental Figure 1 , available on the Blood website; see the Supplemental Materials link at the top of the online article). This is in stark contrast to the results by Roudaia et al, where Y113A/T161A mutant when transduced into 5ЈFU-treated bone marrow cells failed to give third-round colonies. It is possible that 5ЈFU treatment may have depleted certain AML1-ETO target cells that are responsible for the observed phenotype in the assay using positively selected c-kit cells. 5 We also note that the transformation data in Roudaia and colleagues' study had not been normalized with the number of plated cells; that is, colony number in the second and third platings were derived from 10 times more cells (10 4 ) compared with the first plating (10 3 ). 3 If presented as normalized data, the results would look quite significantly different, and the difference between the wild-type and Y113A/T161A mutant would be more modest.
In addition, one must be cautious when interpreting mutagenesis data, as it is almost impossible to engineer absolutely specific mutations that will affect only a single property of the mutated protein. Thus it is critical to have an alternative approach targeting CBF␤ expression without altering the structure of AML1-ETO. Consistent with our point mutant data, we further demonstrated that 2 independent shRNAs that effectively knocked down more than 95% CBF␤ expression at protein level in primary hematopoietic cells did not compromise AML1-ETO-mediated transformation. 2 Together, these results indicate that a significant reduction of CBF␤ activity has only modest effect on AML1-ETO-mediated transformation. However, a decisive experiment to determine whether there is an absolute CBF␤ dependence is to assess the behavior of AML1-ETO in a complete absence of CBF␤ using genetic approaches such as conditional knockout mice that will be instrumental to this issue.
